are prognostic for survival in many cancers and for resistance to fluoropyrimidines in early colon cancer. However, the effect of MMRD and MSI in curatively resected gastric cancer treated with perioperative chemotherapy is unknown.
G astric cancer is the fifth most common cancer and the third most common cause of cancer-related death globally. 1 In Western countries, patients with operable gastric or gastroesophageal adenocarcinoma frequently undergo neoadjuvant or perioperative chemotherapy before surgical resection. 2, 3 This adjunctive chemotherapy is associated with a modest benefit in terms of overall survival (OS) compared with surgery alone but also with toxic effects, including neutropenia and thromboembolic disease. Unfortunately, after optimal multimodality therapy, approximately half of patients undergoing resection will relapse and die of their cancer. There are no validated prognostic biomarkers for patients with gastroesophageal cancer who receive neoadjuvant treatment, and current patient selection is based purely on preoperative radiologic staging. Microsatellite instability (MSI) and mismatch repair (MMR) deficiency (MMRD) are positively prognostic for survival in patients with stage II colon cancer and may be negatively prognostic for the efficacy of fluoropyrimidine adjuvant chemotherapy in the same patient group. 4 ,5 As a consequence, MMR protein status assessment is recommended by the National Comprehensive Cancer Network and the European Society for Medical Oncology guidelines for patients with resected stage II colorectal cancer before adjuvant chemotherapy. 6, 7 For patients with gastric cancer, the prognostic effect of MSI has been suggested in several studies. [8] [9] [10] [11] However, these studies are all retrospective, and each lacked a control group. The United Kingdom Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) trial was an openlabel, multicenter, phase 3 randomized clinical trial that compared the effect of 6 cycles of perioperative epirubicin, cisplatin, and infused fluorouracil chemotherapy (3 cycles before and 3 cycles after resection) plus surgery with surgery alone in patients with resectable gastroesophageal cancer.
2 Patients treated with perioperative chemotherapy had improved OS compared with patients treated with surgery alone (5-year OS, 36% vs 23%; hazard ratio [HR] , 0.75; 95% CI, 0.60-0.93; P = .009). As a result, perioperative epirubicin, cisplatin, and fluorouracil chemotherapy became one standard treatment regimen for patients with resectable gastroesophageal adenocarcinoma. The objectives of this work were to establish the proportion of patients with high MSI (MSI-H) or MMRD cancer in the MAGIC cohort and to evaluate whether the presence or absence of these biomarkers had a prognostic effect on survival in patients treated with surgery alone or chemotherapy plus surgery.
Methods

MSI Assessment
This secondary analysis of the MAGIC trial included participants who were treated with surgery alone or perioperative chemotherapy plus surgery for operable gastroesophageal cancer from July 1, 1994, through April 30, 2002. Genomic DNA was extracted from macrodissected cancer and noncancer tissue using the QIAamp DNA FFPE Tissue Kit (Qiagen). The MSI status was determined using the Promega MSI Analysis System (Promega Corp). A detailed description of the MSI assessment method is in the eMaterial in the Supplement. Tumors were classified as microsatellite stable (MSS) when all markers were stable, as having low MSI (MSI-L) when only 1 marker was unstable, and as MSI-H with minimum instability in 2 markers. 12 The term instability in this context refers to the presence of an increased number of nucleotide repeats in tumor than in the nontumor control DNA for each sample. The MSI-L and MSS tumors were combined for analysis as per previous analyses in gastric cancer.
10,13
MMR Protein Assessment
For MMR protein immunohistochemical analysis, 3-to 4-μm sections were prepared from the tissue microarray blocks and stained for the mutL homologue 1 (MLH1), mutS homologue 2 (MSH2), mutS homologue 6 (MSH6), and PMS1 homologue 2 (PMS2) proteins. The eMaterial in the Supplement provides a detailed description of the immunohistochemical analysis method. Loss of MMR protein expression (MMRD) was designated when none of the neoplastic epithelial cells had nuclear staining while positive internal control nuclei (lymphocytes and stromal cells) were present in the immediate vicinity of the tumor infiltrate. Normal expression was defined as the presence of nuclear staining of tumor cells irrespective of the proportion or intensity.
Tumor Regression Grading Assessment
Two pathologists (M.F., M.R.), who were masked to the treatment arm, reviewed the slides from all cases and graded the pathologic response using the Mandard tumor regression grading (TRG) system. 14 Differences in opinion were resolved by discussion.
Statistical Analysis
Overall survival was calculated from surgery to death from any cause or the last date of follow-up. Meaning Patients with operable gastroesophageal cancer with high microsatellite instability did not benefit from perioperative chemotherapy. Alternative treatment approaches should be investigated for these patients.
was calculated from surgery to the first event (ie, local recurrence or progression, distant recurrence, or death from any cause). Date of surgery was selected as the baseline for biomarker analysis to reduce potential bias because only patients with a surgical specimen were available for inclusion. Analyses were mainly performed within treatment arms because of the differences in timing of surgery to reduce potential bias in the estimates of effects. Interactions between treatment arm and biomarker status were used to highlight potential differences in prognostic effect and were assessed using a Cox proportional hazards regression model. Date of surgery could not be confirmed for 9 patients in the chemotherapy plus surgery arm, and these patients were excluded from the survival analyses. Differences in OS by MSI and MMR protein status were assessed using the Kaplan-Meier method and compared using Cox proportional hazards regression. The Cox proportional hazards regression model was univariate for MSI and MMRD status. All MMR proteins were assessed individually and as a group to include any absent MMR protein. P < .05 was considered statistically significant using 2-sided Cox proportional hazards regression. All analyses were conducted using STATA software, version 14 (StataCorp).
Results
MSI Prevalence and Clinical Characteristics
The MSI results were available for 303 patients (of 456 patients who had undergone resection). Because the data were obtained from resection specimens and analyses examine survival from the date of surgery, only patients who had undergone surgery (456 of 503 enrolled in the MAGIC trial) are potentially included (eFigure in the Supplement).
No difference was found in median survival between patients who had tissue available for MSI analysis and those who did not (20.7 [95% CI, 17.5-28.3] vs 17.9 [95% CI, 13.5-24.2]; HR, 0.91; P < .48). Twenty patients (6.6%) had MSI-H, and 2 (0.7%) had MSI-L. The rate of D2 resection in patients with MSI-H was 55% (vs 41% in the entire MAGIC trial population), and proportions of D2 resections for patients with MSI-H were similar in both arms. Resections were considered by the surgeon to be curative in comparable numbers of patients with MSI-H treated with surgery and surgery plus chemotherapy.
All MSI-H tumors were located in the stomach vs the gastroesophageal junction and esophagus (20 stomach cancers vs 0 gastroesophageal or esophageal tumors, P = .04). A total of 20 of the 234 stomach cancers (8.5%) had MSI-H ( Table 1) . The site of the tumor was not prognostic for survival. Patients with MSI-H tumors compared with MSS or MSI-L tumors were more frequently female and had an older median age. The MSI-H tumors were more frequently of Lauren intestinal histologic subtype and less commonly had metastatic lymph nodes in the resection specimen. None of these differences were statistically significant. A total of 4 (44.4%) of the 9 patients with MSI-H were treated with postoperative chemotherapy, consistent with the proportion of patients in the total trial population.
MSI and Pathologic Response to Chemotherapy
No patient with an MSI-H tumor treated with chemotherapy had a significant pathologic response as measured by a Mandard TRG of 1 or 2 (vs 3-5) in the resection specimen. Of patients with MSS or MSI-L tumors treated with chemotherapy, 20 of 123 (16.3%) had a TRG 1 or 2 response (P = .22 for MSI-H vs MSS or MSI-L). The κ between the 2 pathologists for TRG assessment was 0.64, which increased to 0.70 when the TRG was grouped as TRG 1 and 2 (responders) vs TRG 3 to 5 (nonresponders).
MMRD Prevalence and Clinical Characteristics
Assessment of the MMR protein was performed in 288 MLH1 cases, 282 MSH2 cases, 281 MSH6 cases, and 273 PMS2 cases. The different numbers of cases assessable for each protein reflect exhaustion of tumor material in selected tissue microarrays and resection blocks. All 4 MMR proteins were assessable in 268 cases. In 15 of 288 cases (5.2%), MLH1 was absent; PMS2 was absent in 17 of 273 cases (6.2%); MSH2 was absent in 3 of 282 cases (1.1%); and MSH6 was absent in 2 (0.7%) of 281 cases. Association with MMRD with clinicopathologic characteristics was similar to that for MSI ( Table 2) . 
MMRD and Pathologic Response to Chemotherapy
No patient with MMRD cancer treated with chemotherapy had a good pathologic response to chemotherapy (defined as TRG 1 or TRG 2) compared with 14 of 100 patients (14.0%) with MMR proficiency (MMRP) (P = .36 for comparison of MMRP and MMRD). (Figure 1 ). For patients treated with chemotherapy plus surgery, OS was better for patients with MSS or MSI-L (median OS, 22.5 months; 95% CI, 16.1-42.1 months), whereas median OS for patients with MSI-H was 9.6 months (95% CI, 0.1-21.9 months; HR, 2.22; 95% CI, 1.02-4.85; P =.04)(P = .007 for the interaction between MSI and treatment for OS) (Figure 1 ).
Correlation of MMRD With MSI Status
MMRD and Survival
Patients treated with surgery alone who had MMRD had a median OS that was not reached (95% CI, 4.4 months to not reached); for patients with MMRP tumors, the median OS was 20.7 months (95% CI, 17.5-28.6 months; HR, 0.40; 95% CI, 0.13-1.26; P =.12) (Figure 2 
Discussion
Our study is the first, to our knowledge, to report the differentially prognostic effects of MSI and MMR protein expression on survival in a randomized clinical trial with a nonchemotherapy control arm for perioperatively treated gastroesophageal cancer. We found that patients with MSI-H or MMRD tumors have superior survival compared with patients with MSS/MSI-L or MMRP tumors when treated with surgery alone and conversely have inferior survival to patients with MSS/MSI-L or MMRP tumors when treated with perioperative chemotherapy plus surgery. These findings are significant, because if validated, they suggest that patients with MSI-H or MMRD may not benefit (or may experience a detrimental effect) from perioperative chemotherapy and may be b Excluding those with missing data.
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Mismatch Repair Deficiency, Microsatellite Instability, and Survival in the MAGIC Trial better served by a surgery-only approach. Because MSI or MMRD tumors comprise up to 10% to 20% of stomach cancers in some series, this finding has the potential to affect large numbers of patients.
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Our results are consistent with the results of similar previous Asian and Western retrospective studies 8,10,11,13 that found a significant positive prognostic effect of MSI-H status for patients with resected gastric cancer. In our study, MSI-H and MMRD tumors were only detected in patients with gastric cancer; this finding is commensurate with previous studies 15,16 that found a low prevalence of MSI and MMRD in gastroesophageal junction and esophageal tumors. The consistent effect of MSI-H status on prognosis is supported by a pooled analysis 17 of 17 studies that found an HR for OS of 0.76 (95% CI, 0.65-0.88; P < .001) and limited heterogeneity. In contrast, much fewer data are available on the interaction between MSI status and chemotherapy. In this regard, our results are comparable to the 2 largest retrospective Asian studies 9,13 in which patients with resected gastric cancer were treated with postoperative fluoropyrimidine chemotherapy.
In these retrospective series, patients with stage II and III MSS cancer derived a benefit from adjuvant fluorouracil-based chemotherapy, whereas patients with MSI-H cancer did not. Although our analysis is post hoc, our study is the first randomized clinical trial, to our knowledge, with a control group to validate these findings. In colorectal cancer, the putative prognostic effect of MMR protein status on the benefit of adjuvant chemotherapy is limited to patients with stage II disease. 5 This finding is hypothesized to be attributable to the relatively small benefit associated with adjuvant fluoropyrimidine therapy in patients with stage II colorectal cancer and to the postulated effects of MMRD on the DNA damage response to fluoropyrimidines. 18 First, because the relative benefit of perioperative chemotherapy for gastroesophageal cancer is greater than the benefit of adjuvant chemotherapy in stage II colorectal cancer and second, because cisplatin and epirubicin were used in the MAGIC trial in addition to fluorouracil, our results are possibly unexpected (however, because data on complete nodal staging were absent in a substantial percentage of patients, we cannot de- finitively stage the disease of all patients). One potential explanation for this phenomenon is that the effect of MMRD on the DNA damage response to platinum compounds is differential based on the platinum analog used. 19 The MLH1-deficient cell line models have been reported to be relatively resistant to cisplatin but not oxaliplatin, which in turn reflects the differences in platinum compounds used in the MAGIC trial and colorectal cancer. This circumvention of the DNA damage repair mechanism by oxaliplatin may have important clinical implications; since the MAGIC trial was presented, oxaliplatin has been determined to be clinically equivalent to cisplatin and has replaced it in many gastric cancer chemotherapy regimens. 20 Another hypothesis sidesteps the requirement for chemoresistance: MSI-H tumors are associated with a vigorous immune infiltrate, which may be responsible for suppression of residual micrometastases after surgery. 21, 22 Chemotherapy may have a negative effect on this immunosurveillance, thus reducing the innate benefit of the hypermutated phenotype.
Limitations
A potential limitation of our analysis is that the entire MAGIC cohort was not analyzed because we did not receive tissue from all patients. This limitation affects the numbers analyzed in our study. Furthermore, the low prevalence of MSI and MMRD and the number of events limit the statistical reliability of these data, which as a post hoc analysis should be considered exploratory. However, because survival was not significantly different in those who did not have tissue available for analysis, we do not believe there is a significant bias. One potential confounder of our results is that MSI and MMRD tumors were more likely to be of the Lauren intestinal subtype, which may be associated with improved survival outcomes compared with the diffuse subtype. 23, 24 However, in multivariate analysis of the MAGIC trial, histologic subtype was not an independent prognostic marker of OS. 25 Because we analyzed only resected specimens that had undergone treatment in the chemotherapy arm of the study, to truly determine the prognostic value of MMRD, evaluation of biopsy specimens is required. However, there is no evidence that MMRD status changes after chemotherapy: the equivalent proportion of patients with MMRD in both arms of the trial support this contention. There is an imperfect correlation between MMRD and MSI assessment in our study. This imperfect correlation may be a result of interobserver variability in immunohistochemical analysis assessment, heterogeneity of biomarker expression in gastric cancer, the presence of normally translated but nonfunctional MMR proteins in the setting of a missense MLH1 (OMIM 120436) mutation, or other rare genomic defects that result in MSI-H status with intact MMRD function, such as the polymerase DNA ε1 (POLE) (OMIM 174762) mutation. 
Conclusions
We report for the first time, to our knowledge, in a randomized clinical trial of patients with operable gastroesophageal cancer treated with chemotherapy with a surgery-only control group that the presence of MMRD is associated with a positive prognostic effect in patients treated with surgery alone and a differentially negative prognostic effect in patients treated with chemotherapy plus surgery. If validated, this finding has the potential to improve patient selection for perioperative chemotherapy and spare a significant proportion of patients with gastric cancer unnecessary treatment. We do not believe that these data justify a change in clinical practice; however, we recommend prospective trial validation to ascertain the optimal perioperative treatment for patients with MSI-H gastric cancer. In light of the remarkable success of anti-programmed cell death protein 1 therapies in MMRD colorectal cancer, alternative treatment strategies could be reasonably investigated for these patients. 
eMaterial. Detailed Study Methods and Results
Methods
A. Detailed PCR methodology
The PCR was performed on a 2720 Thermal Cycler (Applied Biosystems, CA, USA) using the following PCR cycling conditions; initial denaturation (11 min at 95°C, 2 min at 96°C), followed by 10 cycles denaturation (1 min at 94°C), annealing (1 min at 58°C) and extension (90 sec at 70°C), followed by 20 cycles denaturation (1 min at 90°C), annealing (1 m in at 58°C) and extension (90 sec at 70°C). There was a final step of 30 min at 60°C then hold at 4°C. The samples were run on an Applied Biosystems® 3500 Genetic Analyzer and POP -7™ polymer and analysed using GeneMapper™ v5.0 software (Applied Biosystems, CA, USA).
B. Detailed tissue microarray construction methodology
Tissue microarrays (TMAs) were constructed from representative blocks from the trial specimens, and were composed of replicate 1-mm cores from each case and controls (i.e.
samples of non-neoplastic kidney, liver, placenta, small bowel or normal stomach) as previously described. 14 In the case of TMA exhaustion further slides were cut from the resection block if possible.
C. Detailed slide preparation methodology
Sections were deparaffinised using EZ Prep solution (Ventana Corp.). CC1 standard (pH 8.4
buffer containing Tris/borate/ EDTA) was used for antigen retrieval and blocked with inhibitor D (3% H2O2) for 4 min at 37°C. Slides were incubated with primary antibody for 40 min at 37°C followed by a universal secondary antibody for 20 min at 37°C. Slides were incubated with streptavidin-horseradish peroxidase (SA-HRP) D for 16 min at 37°C followed by addition of substrate, 3, 3´-diaminobenzidine tetrahydrochloride (DAB) H2O2 for 8 min. The sections were counterstained by hematoxylin and bluing at 37°C
D. Detailed immunohistochemistry methodology
Immunohistochemical staining was performed using a VentanaXT automated platform 
Results
A. Progression free survival analysis in MSI-H vs. MSS/MSI-L patients
Patients treated with surgery alone who were MSI-H had a median progression free survival 
B. Progression free survival analysis in MMRD vs MMR proficient patients
For patients who were mismatch repair deficient in any protein and treated with surgery alone median progression free survival was not reached (95% CI 4.4 months -not reached), whereas this was 17.4 months (95% CI 14.1 months -23.7 months for patients who were intact for all mismatch repair proteins, HR 0.51 (95% CI 0.19 -1.38, p= 0.186).
For chemotherapy treated patients who were mismatch repair deficient median progression free survival was 15 months (95% CI 0.2 -42.4 months) compared to for mismatch repair proficient patients treated with chemotherapy who had a median progression free survival of 19.6 months (95% CI 15.5-35.2 months), HR 1.47 (95% CI 0.71 -3.07), p=0.301.
C. Overall survival analysis according to specific MMRD protein
For patients treated with surgery alone, those with MLH1 deficiency had better OS than MLH1 proficient patients as median OS was not reached for MLH1 deficient patients (95% for patients who were PMS2 proficient (HR 1.90 (95% CI 0.91-3.97) p= 0.087 . Median OS for patients with MSH2 and MSH6 deficiency was not calculable due to small numbers of patients in these groups (each had one patient and one death).
The interaction test between MLH1 and treatment arm was 0.01
